AstraZeneca Pharma signs distribution agreement with Abbott Healthcare

Franchise India Bureau December 10 2018 - 2 min read
AstraZeneca Pharma signs distribution agreement with Abbott Healthcare
Dapagliflozin, an innovative Type 2 diabetes medicine, is a leading diabetes medicine of AstraZeneca Pharma.

Drug firm AstraZeneca Pharma India has inked a distribution agreement with Abbott Healthcare to distribute a diabetes medicine 'Dapagliflozin' in India. Dapagliflozin, an innovative Type 2 diabetes medicine, is a leading diabetes medicine of AstraZeneca Pharma. 

AstraZeneca Pharma said, "Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET."

The drug company will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.

Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities